Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000581557 | SCV000689216 | likely benign | Hereditary cancer-predisposing syndrome | 2016-12-08 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000759692 | SCV000889185 | uncertain significance | not provided | 2018-04-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001084889 | SCV001126539 | likely benign | Hereditary breast ovarian cancer syndrome | 2024-08-21 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001174725 | SCV001338003 | likely benign | not specified | 2024-12-18 | criteria provided, single submitter | clinical testing | Variant summary: BRCA2 c.9649-9T>G alters a conserved nucleotide located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The frequency data for this variant in gnomAD is considered unreliable, as metrics indicate poor data quality at this position. To our knowledge, no occurrence of c.9649-9T>G in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 491385). Based on the evidence outlined above, the variant was classified as likely benign. |
All of Us Research Program, |
RCV004001326 | SCV004830083 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-10-02 | criteria provided, single submitter | clinical testing | |
Genomics and Molecular Medicine Service, |
RCV005240234 | SCV005882947 | uncertain significance | Inherited breast cancer and ovarian cancer | 2024-09-30 | criteria provided, single submitter | clinical testing | BP4 |